BACKGROUND: Keratoacanthomas, as well as an actinic keratosis progressing to squamous cell cancer, have been reported in patients who were treated with sorafenib, a multikinase inhibitor known to suppress the actions of Raf kinase and vascular endothelial growth factor receptor. OBSERVATIONS: We describe a 70-year-old white woman with metastatic renal cell carcinoma who was treated with a combination of sorafenib and tipifarnib (a farnesyltransferase inhibitor). She had no history of skin cancer. However, within 3 months after starting this therapy, she developed 3 erythematous nodules on her legs. Pathologic examination showed deeply invasive, well-differentiated squamous cell carcinomas. The tumors were excised, and sorafenib-tipifarnib treatment was discontinued. No new lesions have developed to date. CONCLUSIONS: Targeted agents, such as sorafenib and tipifarnib, are increasingly being used in the management of visceral malignant neoplasms. A temporal relationship was observed between the initiation of the targeted treatments and the emergence of these cutaneous cancers. Further study of the mechanisms responsible for the rapid appearance of squamous cell cancers in this setting may provide insights into the pathogenesis of skin tumors.
BACKGROUND:Keratoacanthomas, as well as an actinic keratosis progressing to squamous cell cancer, have been reported in patients who were treated with sorafenib, a multikinase inhibitor known to suppress the actions of Raf kinase and vascular endothelial growth factor receptor. OBSERVATIONS: We describe a 70-year-old white woman with metastatic renal cell carcinoma who was treated with a combination of sorafenib and tipifarnib (a farnesyltransferase inhibitor). She had no history of skin cancer. However, within 3 months after starting this therapy, she developed 3 erythematous nodules on her legs. Pathologic examination showed deeply invasive, well-differentiated squamous cell carcinomas. The tumors were excised, and sorafenib-tipifarnib treatment was discontinued. No new lesions have developed to date. CONCLUSIONS: Targeted agents, such as sorafenib and tipifarnib, are increasingly being used in the management of visceral malignant neoplasms. A temporal relationship was observed between the initiation of the targeted treatments and the emergence of these cutaneous cancers. Further study of the mechanisms responsible for the rapid appearance of squamous cell cancers in this setting may provide insights into the pathogenesis of skin tumors.
Authors: Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Anita Schwandt; Vivian E von Gruenigen; Robert M Wenham; Heidi Frasure; Susan Eaton; Nancy Fusco; Pingfu Fu; John J Wright; Afshin Dowlati; Steven Waggoner Journal: Invest New Drugs Date: 2014-03-12 Impact factor: 3.850
Authors: Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach Journal: J Am Acad Dermatol Date: 2012-05-18 Impact factor: 11.527
Authors: Gerald S Falchook; Peter Rady; Sharon Hymes; Harrison P Nguyen; Stephen K Tyring; Victor G Prieto; David S Hong; Razelle Kurzrock Journal: JAMA Dermatol Date: 2013-03 Impact factor: 10.282
Authors: Tatiana C Schneider; Ellen Kapiteijn; Tom van Wezel; Jan W A Smit; Jacobus J M van der Hoeven; Hans Morreau Journal: BMC Cancer Date: 2016-01-19 Impact factor: 4.430
Authors: Alastair J King; Marc R Arnone; Maureen R Bleam; Katherine G Moss; Jingsong Yang; Kelly E Fedorowicz; Kimberly N Smitheman; Joseph A Erhardt; Angela Hughes-Earle; Laurie S Kane-Carson; Robert H Sinnamon; Hongwei Qi; Tara R Rheault; David E Uehling; Sylvie G Laquerre Journal: PLoS One Date: 2013-07-03 Impact factor: 3.240